Aft Pharmaceuticals Ltd
AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, pain management, skin care, vitamins, supplements, gastrointestinal, … Read more
Market Cap & Net Worth: Aft Pharmaceuticals Ltd (AFP)
Aft Pharmaceuticals Ltd (AU:AFP) has a market capitalization of $185.71 Million (AU$299.92 Million) as of March 18, 2026. Listed on the AU stock exchange, this Australia-based company holds position #20871 globally and #365 in its home market, demonstrating a -4.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aft Pharmaceuticals Ltd's stock price AU$2.86 by its total outstanding shares 104866260 (104.87 Million).
Aft Pharmaceuticals Ltd Market Cap History: 2016 to 2026
Aft Pharmaceuticals Ltd's market capitalization history from 2016 to 2026. Data shows change from $171.13 Million to $185.71 Million (-0.25% CAGR).
Index Memberships
Aft Pharmaceuticals Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Australia All Ordinaries
AORD
|
$457.28 Billion | 0.01% | #147 of 495 |
Weight: Aft Pharmaceuticals Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aft Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aft Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.95x
Aft Pharmaceuticals Ltd's market cap is 0.95 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
16.28x
Aft Pharmaceuticals Ltd's market cap is 16.28 times its annual earnings
10.35x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $171.13 Million | $64.01 Million | -$13.27 Million | 2.67x | N/A |
| 2017 | $135.61 Million | $69.20 Million | -$18.39 Million | 1.96x | N/A |
| 2018 | $127.54 Million | $81.18 Million | -$13.62 Million | 1.57x | N/A |
| 2019 | $200.18 Million | $85.13 Million | -$3.36 Million | 2.35x | N/A |
| 2020 | $328.69 Million | $105.60 Million | $12.69 Million | 3.11x | 25.90x |
| 2021 | $253.78 Million | $113.11 Million | $7.78 Million | 2.24x | 32.61x |
| 2022 | $219.56 Million | $130.31 Million | $19.85 Million | 1.68x | 11.06x |
| 2023 | $210.29 Million | $156.64 Million | $10.65 Million | 1.34x | 19.74x |
| 2024 | $165.58 Million | $194.03 Million | $15.61 Million | 0.85x | 10.61x |
| 2025 | $194.80 Million | $205.49 Million | $11.96 Million | 0.95x | 16.28x |
Competitor Companies of AFP by Market Capitalization
Companies near Aft Pharmaceuticals Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Aft Pharmaceuticals Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Aft Pharmaceuticals Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Aft Pharmaceuticals Ltd's market cap moved from $171.13 Million to $ 185.71 Million, with a yearly change of -0.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$185.71 Million | -4.67% |
| 2025 | AU$194.80 Million | +17.65% |
| 2024 | AU$165.58 Million | -21.26% |
| 2023 | AU$210.29 Million | -4.22% |
| 2022 | AU$219.56 Million | -13.48% |
| 2021 | AU$253.78 Million | -22.79% |
| 2020 | AU$328.69 Million | +64.19% |
| 2019 | AU$200.18 Million | +56.96% |
| 2018 | AU$127.54 Million | -5.95% |
| 2017 | AU$135.61 Million | -20.76% |
| 2016 | AU$171.13 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Aft Pharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $185.71 Million USD |
| MoneyControl | $185.71 Million USD |
| MarketWatch | $185.71 Million USD |
| marketcap.company | $185.71 Million USD |
| Reuters | $185.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.